Black Creek Investment Management Inc. Has $262.45 Million Stake in Hologic, Inc. $HOLX

Black Creek Investment Management Inc. grew its position in Hologic, Inc. (NASDAQ:HOLX) by 26.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,027,829 shares of the medical equipment provider’s stock after buying an additional 832,444 shares during the period. Hologic accounts for about 12.1% of Black Creek Investment Management Inc.’s portfolio, making the stock its 2nd largest position. Black Creek Investment Management Inc. owned approximately 1.81% of Hologic worth $262,453,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. Chung Wu Investment Group LLC purchased a new stake in Hologic during the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic during the 1st quarter valued at $34,000. Cromwell Holdings LLC boosted its position in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in Hologic during the 1st quarter worth $42,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of a number of research analyst reports. Evercore ISI set a $78.00 price target on Hologic and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Leerink Partners increased their price objective on shares of Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday, October 21st. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $78.00 target price on shares of Hologic in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $79.77.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by company insiders.

Hologic Trading Down 0.0%

Shares of Hologic stock opened at $74.14 on Tuesday. The stock has a market cap of $16.49 billion, a PE ratio of 30.76, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The firm has a fifty day moving average price of $69.92 and a 200 day moving average price of $65.90. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $1.01 EPS. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.